Deciphera- Tirabrutinib vs Rituximab & Temozolomide in Relapsed/Refractory PCNSL (ONO-4059-17)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
Principal Investigator
Headshot of Katherine Barnett Peters
Professor of Neurosurgery
Protocol Number
IRB: PRO00119479
NCT: NCT07104032
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate